The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (such as Alzheimer’s disease), and other age-related conditions. This has positioned NLRP3 as a promising pharmacological target. Numerous studies have shown that complete NLRP3 ablation can prevent or mitigate these diseases. However, total elimination of NLRP3 is not a feasible therapeutic strategy for the millions of patients affected by these degenerative disorders. Consequently, drug development efforts have focused on partial inhibition of NLRP3 using compounds that reduce its expression or activity. Paradoxically, although many studies have used Nlrp3 knockout mouse models, Nlrp3 haploinsufficient mice—more representative of the effects of pharmacological inhibition—are rarely included and remain poorly characterized. Here, we report the long-term effects of Nlrp3 haploinsufficiency during aging. Although no overt differences were observed in early life, by 16 months of age, Nlrp3 heterozygous mice exhibited signs of accelerated inflammatory aging, driven by compensatory overexpression of NLRP1. Mechanistic studies provide evidence of a previously unidentified interaction between NLRP1 and NLRP3, forming a hybrid inflammasome that drives NLRP1-mediated inflammatory overactivation when NLRP3 expression is reduced. Accordingly, anti-inflammatory treatment provided notable but moderate improvement of the inflammatory phenotype, whereas genetic inhibition of Nlrp1 more consistently reduced inflammation and extended health span. Our findings reveal a previously unidentified compensatory interaction between NLRP1 and NLRP3 and suggest that multiinflammasome inhibition may offer a more effective strategy for treating aging and age-related diseases.
Nutraceuticals, bioactive compounds derived from foods, are increasingly investigated as interventions to promote healthy ageing. Multi-ingredient formulations may offer additive or synergistic benefits by targeting multiple ageing pathways while using low doses of each component for improved safety. However, their efficacy in mammals remains poorly understood. Here, we compared the effects of a continuous multi-ingredient nutraceutical intervention with two short-courses of senolytic regimen in naturally aged male C57Bl/6J mice. Importantly, these mice were overweight following a switch to soaked food at 20 months, a protocol that increased caloric intake and likely induced metabolic stress. This context frames the study as a model of ‘rescue’ from premature ageing rather than extension of maximum lifespan. Mice were assigned to either control, nutraceutical (12 pro-longevity natural compounds), or senolytic (Navitoclax plus BAM15) groups at 20 months of age. Lifespan and healthspan indicators were assessed longitudinally. Both interventions improved survival compared to controls (median lifespan +18–21%) and mitigated frailty progression, but with distinct patterns: nutraceutical benefits accumulated gradually, whereas senolytic effects were transient. Cognitive performance was preserved in nutraceutical-treated mice and improved shortly after senolytic treatment. In vitro, the nutraceutical lacked senolytic activity but exhibited senostatic effects, reducing nuclear size, ROS release, and IL-6 secretion in senescent fibroblasts. These findings suggest that multi-ingredient nutraceuticals can restore healthspan compromised by metabolic stress and deliver benefits comparable to senolytics when administered continuously, potentially through senostatic mechanisms. Combining senolytics to reduce senescent burden with long-term nutraceutical treatment may offer a safe, accessible strategy to optimise healthspan, particularly in the context of modern human ageing, which often occurs under conditions of caloric excess and metabolic syndrome.